MADIA will develop a versatile and cost-effective in-vitro tool for early diagnosis of Alzheimer’s and Parkinson’s diseases. Alzheimer’s and Parkinson’s diseases, the two most common neurodegenerative disorder worldwide, are debilitating and largely untreatable conditions that are strongly linked with age.
Alzheimer’s is the most common form of dementia, affecting seven million across Europe. The global cost of dementia in 2015 was around US$ 820 billion, meaning that age-related neurodegenerative disease is one of the largest medical and societal challenges faced by our society.
Costs of dementia in 2015 (billion US$), by G7 and G20 country classification
(Source: World Alzheimer Report 2015 - The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends.)